World Library  
Flag as Inappropriate
Email this Article

Cinacalcet

Article Id: WHEBN0001903249
Reproduction Date:

Title: Cinacalcet  
Author: World Heritage Encyclopedia
Language: English
Subject: ATC code H05, Tertiary hyperparathyroidism, Teriparatide, Hyperparathyroidism, Allosteric regulation
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cinacalcet

Cinacalcet
Systematic (IUPAC) name
(R)-N-[1-(1-naphthyl)ethyl]-3-
[3-(trifluoromethyl)phenyl]propan-1-amine
Clinical data
AHFS/Drugs.com
MedlinePlus
Licence data EMA:, US FDA:
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Legal status
  • (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 20 to 25%
Increases if taken with food
Protein binding 93 to 97%
Metabolism Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated)
Biological half-life 30 to 40 hours
Excretion Renal (80%) and fecal (15%)
Identifiers
CAS Registry Number  Y
ATC code H05
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  Y
ChEMBL  N
Chemical data
Formula C22H22F3N
Molecular mass 357.412 g/mol
 N   

Cinacalcet (Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of end-stage renal disease.[1] Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.[2] Cinacalcet was FDA approved in March 2004. [3]

Contents

  • Medical uses 1
  • Contraindications 2
  • Adverse effects 3
  • Overdose 4
  • Drug interactions 5
  • Dosing 6
  • Monitoring 7
  • Safety in pregnancy and lactation 8
  • Mechanism of action 9
  • References 10
  • External links 11

Medical uses

Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in people with chronic kidney disease on dialysis and hypercalcemia in people with parathyroid carcinoma.[4] Cinacalcet can also be used to treat severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy. [5]

In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis it does not appear to affect mortality.[6] It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels.[6]

Contraindications

Hypocalcemia (decreased calcium levels) is a contraindication of cinacalcet. Patients who have serum calcium levels less than 7.5 mg/dL should not be started on cinacalcet. Hypocalcemia symptoms include parathesias, myalgias, muscle cramping, tetany, and convulsions. Cinacalcet should not be administered until serum calcium levels are above 8.0 mg/dL and/or hypocalcemia symptoms are resolved. [3]

Adverse effects

Common side effects of cinacalcet include:[5]

  • Stomach upset
  • Vomiting
  • Diarrhea
  • Dizziness
  • Nausea
  • Weakness
  • Chest pain

Clinical trials conducted in the United States by Amgen to determine whether the drug is safe for children were halted by the FDA in February 2013 following the death of a 14-year-old patient.[7]

Overdose

Serious side effects, including overdose symptoms, of cinacalcet include:[5]

  • Burning
  • Tingling
  • Unusual feelings of the lips, tongue, fingers, or feet
  • Muscle aches or cramps
  • Sudden tightening of muscles in hands, feet, face, or throat
  • Seizures

Drug interactions

Cinacalcet is a strong CYP2D6 inhibitor and is partially metabolized by CYP3A4 and CYP1A2. Dose adjustments may be necessary if patients are on CYP3A4 and CYP1A2 inhibitors and medications that are metabolized by CYP2D6. [3]

Dosing

Cinacalcet is taken orally and comes in tablet form in three strengths (30 mg, 60 mg, and 90 mg). [8] The tablet should not be split, chewed, or crushed. Cinacalcet should be taken with food or after a meal for increased absorption of the medication. Cinacalcet dosing is patient dependent and individualized. [5]

Monitoring

Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis

Intact parathyroid hormone (iPTH) levels should be monitored and should not be measured earlier than 12 hours after the last dose. iPTCH levels are usually measured 1 to 4 weeks after the initiation dose or dose adjustment, and every 1 to 3 months after the maintenance dose is established. Serum calcium and phosphorus levels should be within 1 week after starting cinacalcet or after dose adjustment. Once the maintenance dose is established, serum calcium should be measured monthly. [3]

Parathyroid Carcinoma or Primary Hyperparathyroidism

Serum calcium should be measured 1 week after initiation or dose adjustment of cinacalcet, and every 2 months once the maintenance dose has been established. [3]

Safety in pregnancy and lactation

Pregnancy

Cinacalcet is category C in pregnancy. Adequate and well-controlled studies involving cinacalcet in pregnant women have not been done; therefore cinacalcet should only be used during pregnancy if the benefit outweighs the potential risk to the fetus. [3]

Lactation

Studies have not been done in lactating women; therefore it is not known whether cinacalcet is excreted in human milk. [3]

Mechanism of action

Cinacalcet is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. The calcium-sensing receptors on the surface of the chief cell of the parathyroid gland is the principal regulator of parathyroid hormone secretion (PTH). [9] Cinacalcet increases the sensitivity of calcium receptors on parathyroid cells to reduce parathyroid hormone (PTH) levels and thus decrease serum calcium levels. [4] As receptors are already active from the calcimimetic (Cinacalcet) the native rise and fall of Ca levels now interact with the remaining receptors, effectively lowering the threshold for activation of feedback on the parathyroid chief cells.

References

  1. ^ Torres PU (2006). "Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease". Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 16 (3): 253–8.  
  2. ^ "Sensipar for Parathyroid Carcinoma". Amgen. 2009. Retrieved 25 September 2009. 
  3. ^ a b c d e f g
  4. ^ a b 2014 Nurses Drug Handbook (13th ed.). Burlington, MA: Jones & Bartlett Learning. 2014. pp. 245–6.  
  5. ^ a b c d
  6. ^ a b Ballinger, AE; Palmer, SC; Nistor, I; Craig, JC; Strippoli, GF (9 December 2014). "Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.". The Cochrane database of systematic reviews 12: CD006254.  
  7. ^ Edney, Anna (February 26, 2013). "Amgen Pediatric Trials of Sensipar Halted by FDA After Death". Businessweek. 
  8. ^ Sensipar (Cinacalcet). Amgen. [6]. Retrieved 29 October 2014.
  9. ^ http://www.drugbank.ca/drugs/DB01012

External links

  • Sensipar website run by Amgen
  • Prescribing information (package insert)
  • Cinacalcet - Medlineplus.org
  • Cinacalcet - Drug Digest.
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.